Search

Displaying results 9631 - 9640 of 9860 in total
  1. Drug

    Tralesinidase alfa

    go.drugbank.com/drugs/DB17657
    Investigational

    Tralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2.

  2. Drug

    GTP-506

    go.drugbank.com/drugs/DB17682
    Experimental

    GTP-506 is a gene therapy formed by two vectors, a nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a therapeutic donor vector that inserts the OTC gene to provide

  3. Drug

    CB-010

    go.drugbank.com/drugs/DB17711
    Investigational

    CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is being investigated for the treatment of follicular lymphoma.[L46158]

  4. Drug

    Mozafancogene autotemcel

    go.drugbank.com/drugs/DB17723
    Investigational

    RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A

    Synonyms: Autologous CD34+ HSPCs Transduced with LV Carrying FANCA Gene RP
  5. Drug

    NKTT-120

    go.drugbank.com/drugs/DB17730
    Investigational

    NKTT-120 is a recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR).

  6. Drug

    Ammonium trichlorotellurate

    go.drugbank.com/drugs/DB17740
    Investigational

    Ammonium trichlorotellurate is an investigational compound with anti-tumour and anti-inflammatory properties.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Libivirumab

    go.drugbank.com/drugs/DB17748
    Experimental

    It is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]

  8. Drug

    MBL-HCV1

    go.drugbank.com/drugs/DB17776
    Investigational

    MBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients receiving a liver transplant.

  9. Drug

    Cry5B

    go.drugbank.com/drugs/DB17783
    Experimental

    Cry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_.

  10. Drug

    Rivabazumab pegol

    go.drugbank.com/drugs/DB17788
    Investigational

    Rivabazumab pegol is being investigated as a treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis.[A259457]

    Synonyms: KB001-A, KB001-A (AN ANTI-PCRV PEGYLATED MONOCLONAL ANTIBODY FRAGMENT TO THE TYPE III SECRETION SYSTEM OF PSEUDOMONAS AERUGINOSA)